pharma · Non-transfusion-dependent Thalassemia · Advanced Solid Tumors · SLN
Silence Therapeutics
Silence Therapeutics plc
Silence Therapeutics is a pharma organization headquartered in London, GB. It trades on NYSE under ticker SLN. Primary therapeutic focus areas include Non-transfusion-dependent Thalassemia, Advanced Solid Tumors, Carcino
London, GB HQ
1999 Founded
91 Employees
Public company Type
SLN · NYSE Ticker
Company details
- Status
- Public
- HQ
- London, GB
- Founded
- 1999
- Employees
- 91
- Programs
- 8
- Drugs
- 6
- Patents
- 3
Atu027 & gemcitabine in lead in safety period
Phase 2 · small molecule · Carcinoma, Pancreatic Ductal
Atu027 & gemcitabine in lead in safety period for Carcinoma, Pancreatic Ductal is a Phase 2 program (small_molecule) at Silence Therapeutics plc with 1 ClinicalTrials.gov record(s).
Internal code Atu027-I-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Silence Therapeutics plc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Carcinoma, Pancreatic Ductal
- Status
- completed
- Trials
- 1